Baillie Gifford & Co
DNLI icon

Baillie Gifford & Co’s Denali Therapeutics DNLI Stock Holding History

Quarter Market Value Status Shares Shares
Change %
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$167M Sell
11,955,323
-134,717
-1% -$1.88M 0.12% 106
2025
Q1
$164M Sell
12,090,040
-223,891
-2% -$3.04M 0.14% 108
2024
Q4
$251M Sell
12,313,931
-1,031,956
-8% -$21M 0.19% 84
2024
Q3
$389M Sell
13,345,887
-417,709
-3% -$12.2M 0.29% 68
2024
Q2
$320M Sell
13,763,596
-277,632
-2% -$6.45M 0.25% 77
2024
Q1
$288M Sell
14,041,228
-219,496
-2% -$4.5M 0.22% 83
2023
Q4
$306M Sell
14,260,724
-420,303
-3% -$9.02M 0.24% 83
2023
Q3
$303M Sell
14,681,027
-162,743
-1% -$3.36M 0.28% 76
2023
Q2
$438M Sell
14,843,770
-508,341
-3% -$15M 0.37% 61
2023
Q1
$354M Buy
15,352,111
+232,637
+2% +$5.36M 0.32% 71
2022
Q4
$420M Buy
15,119,474
+404,423
+3% +$11.2M 0.44% 63
2022
Q3
$452M Sell
14,715,051
-154,323
-1% -$4.74M 0.47% 56
2022
Q2
$438M Sell
14,869,374
-111,058
-0.7% -$3.27M 0.45% 65
2022
Q1
$482M Sell
14,980,432
-75,949
-0.5% -$2.44M 0.34% 71
2021
Q4
$672M Buy
15,056,381
+46,565
+0.3% +$2.08M 0.37% 69
2021
Q3
$757M Sell
15,009,816
-137,797
-0.9% -$6.95M 0.4% 66
2021
Q2
$1.19B Buy
15,147,613
+2,152,416
+17% +$169M 0.58% 43
2021
Q1
$742M Buy
12,995,197
+804,941
+7% +$46M 0.42% 61
2020
Q4
$1.02B Buy
12,190,256
+1,363,078
+13% +$114M 0.57% 41
2020
Q3
$388M Buy
10,827,178
+1,547,984
+17% +$55.5M 0.27% 71
2020
Q2
$224M Buy
9,279,194
+149,442
+2% +$3.61M 0.17% 93
2020
Q1
$160M Buy
9,129,752
+1,539,505
+20% +$27M 0.17% 88
2019
Q4
$132M Buy
7,590,247
+226,784
+3% +$3.95M 0.13% 100
2019
Q3
$113M Sell
7,363,463
-43,766
-0.6% -$671K 0.13% 99
2019
Q2
$154M Buy
7,407,229
+1,145,003
+18% +$23.8M 0.16% 93
2019
Q1
$145M Buy
6,262,226
+34,502
+0.6% +$801K 0.16% 89
2018
Q4
$129M Buy
6,227,724
+741,303
+14% +$15.3M 0.17% 87
2018
Q3
$119M Buy
5,486,421
+141,788
+3% +$3.08M 0.13% 88
2018
Q2
$81.5M Buy
5,344,633
+151,787
+3% +$2.31M 0.09% 96
2018
Q1
$102M Buy
5,192,846
+271,063
+6% +$5.34M 0.12% 85
2017
Q4
$77M Buy
+4,921,783
New +$77M 0.1% 90